Juglanin inhibits lung cancer by regulation of apoptosis, ROS and autophagy induction
Metrics: PDF 1319 views | HTML 1791 views | ?
Liang Chen1, Ya-Qiong Xiong1, Jing Xu1, Ji-Peng Wang1, Zi-Li Meng1 and Yong-Qing Hong1
1Department of Respiration, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, Jiangsu 223300, China
Zi-Li Meng, email: email@example.com
Yong-Qing Hong, email: firstname.lastname@example.org
Keywords: juglanin, lung cancer, apoptosis, ROS, autophagy
Received: June 27, 2017 Accepted: August 27, 2017 Published: September 28, 2017
Juglanin (Jug) is obtained from the crude extract of Polygonum aviculare, exerting suppressive activity against cancer cell progression in vitro and in vivo. Juglanin administration causes apoptosis and reactive oxygen species (ROS) in different types of cells through regulating various signaling pathways. In our study, the effects of juglanin on non-small cell lung cancer were investigated. A significant role of juglanin in suppressing lung cancer growth was observed. Juglanin promoted apoptosis in lung cancer cells through increasing Caspase-3 and poly ADP-ribose polymerase (PARP) cleavage, which is regulated by TNF-related apoptosis-inducing ligand/Death receptors (TRAIL/DRs) relied on p53 activation. Anti-apoptotic members Bcl-2 and Bcl-xl were reduced, and pro-apoptotic members Bax and Bad were enhanced in cells and animals receiving juglanin. Additionally, nuclear factor-κB (NF-κB), phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) and mitogen-activated protein kinases (MAPKs) activation were inhibited by juglanin. Further, juglanin improved ROS and induced autophagy. ROS inhibitor N-acetyl-l-cysteine (NAC) reversed apoptosis induced by juglanin in cancer cells. The formation of autophagic vacoules and LC3/autophagy gene7 (ATG7)/Beclin1 (ATG6) over-expression were observed in juglanin-treated cells. Also, juglanin administration to mouse xenograft models inhibited lung cancer progression. Our study demonstrated that juglanin could be a promising candidate against human lung cancer progression.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.